Issuance of Stock Acquisition Rights as Stock-Based Compensation for Directors
First written in FY2017-Q2. 9 of 15 entries say "Achieved", first in FY2018-Q2. Latest entry: 2026-10-05.
37 other companies' latest entry also says "Achieved".
- FY2025-H1AchievedAnnual report
「Treasury shares decreased by 117,690 shares as a result of the disposal of treasury shares carried out on 30 September 2024 as restricted stock compensation.」
We disposed of 117,690 treasury shares as restricted stock compensation, implementing the directors' stock-based compensation system. - FY2024-Q1AchievedAnnual report
「The number of shares increased by 109,870 as of 29 September 2023 through the issuance of new shares as restricted stock compensation, as resolved at a meeting of the Board of Directors held on 12 September 2023.」
We issued 109,870 new shares as restricted stock compensation on 29 September 2023, implementing the directors' stock-based compensation system. - FY2023-Q2AchievedAnnual report
「4 October 2022 (Note) Paid third-party allotment as restricted stock compensation Issue price: ¥651 per share Amount included in capital: ¥326 per share Allottees: 6 directors (excluding outside directors)」
We issued 72,860 shares through a paid third-party allotment as restricted stock compensation to 6 directors. - FY2022-Q2AchievedAnnual report
「13 October 2021 (Note 1) Paid third-party allotment as restricted stock compensation Issue price: ¥814 per share Amount included in capital: ¥407 per share Allottees: 6 directors (excluding outside directors)」
We issued 58,270 shares through a paid third-party allotment of restricted stock compensation to 6 directors. - FY2021RestatedAnnual report
「We paid monetary compensation claims to the Company's directors, excluding outside directors, as compensation relating to restricted shares, pursuant to a resolution of the Board of Directors, in an amount of up to ¥65 million per year (revised to ¥200 million per year at the 35th Annual General Meeting of Shareholders held on 26 August 2021)」
We disclosed the details of the directors' compensation system changed from stock acquisition rights to restricted shares, including the compensation amount and restriction period. - FY2021-Q2AchievedAnnual report
「1 October 2020 (Note 2) 49,300 9,615,515 19 1,251 19 1,198 (Note) 2. Paid third-party allotment as restricted stock compensation Issue price: ¥800 per share Amount included in capital: ¥400 per share Allottees: 6 directors (excluding outside directors)」
We issued 49,300 shares through a paid third-party allotment as restricted stock compensation for 6 directors, implementing the compensation system change announced in the previous fiscal year. - FY2020ReframedAnnual report
「It was resolved to abolish the provisions governing the amount of compensation and other payments relating to these stock acquisition rights as stock-based stock options, and to set the total amount of monetary compensation claims to be paid to eligible directors as compensation relating to restricted shares at no more than ¥65 million per year, within the total annual amount of compensation and other payments for directors of ¥500 million.」
We resolved a policy to change directors' stock-based compensation from stock acquisition rights to restricted shares. The purpose of sharing the benefits and risks of share price movements with shareholders was also stated. - FY2020-Q2AchievedAnnual report
「(1) Name of the stock acquisition rights: PharmaRise Holdings Corporation Seventh Stock-Based Compensation Stock Acquisition Rights (2) Eligible recipients and number: 6 directors of the Company (excluding outside directors) (3) Number of stock acquisition rights The number of stock acquisition rights granted to the Company's directors is 8,116.」
We issued 8,116 Seventh Stock-Based Compensation Stock Acquisition Rights to 6 directors excluding outside directors. The exercise period is from 18 September 2019 to 17 September 2049. - FY2019-Q2AchievedAnnual report
「Stock acquisition rights issued during the second-quarter accounting period were as follows.」
With 18 September 2018 as the allocation date, we issued 8,136 Sixth Stock-Based Compensation Stock Acquisition Rights, representing 81,360 underlying shares, to 6 directors. The allocation plan disclosed in the previous fiscal year was implemented. - FY2018AdvancedAnnual report
「(1) Name of the stock acquisition rights: PharmaRise Holdings Corporation Sixth Stock-Based Compensation Stock Acquisition Rights (2) Eligible recipients and number: 6 directors of the Company (excluding outside directors) (3) Number of stock acquisition rights: The number of stock acquisition rights granted to the Company's directors is 8,136.」
We disclosed a plan to allocate 8,136 Sixth Stock-Based Compensation Stock Acquisition Rights to 6 directors excluding outside directors, based on the resolution dated 28 August 2018. - FY2018-Q2AchievedAnnual report
「The stock acquisition rights issued during the second quarter under review were as follows. Number of stock acquisition rights (rights) 6,623 Number of underlying shares (shares) 66,230」
With 14 September 2017 as the allocation date, we issued 6,623 Fifth Stock-Based Compensation Stock Acquisition Rights, representing 66,230 underlying shares, to 3 directors excluding outside directors. - FY2017AdvancedAnnual report
「(1) Name of the stock acquisition rights: PharmaRise Holdings Corporation Fifth Stock-Based Compensation Stock Acquisition Rights (2) Eligible recipients and number: 3 directors of the Company (excluding outside directors) (3) Number of stock acquisition rights The number of stock acquisition rights granted to the Company's directors is 6,623.」
The Company newly disclosed a plan to issue the Fifth Stock-Based Compensation Stock Acquisition Rights based on a resolution of the Board of Directors dated 24 August 2017. The plan covers 3 directors excluding outside directors and provides for 6,623 rights. - FY2017-Q2First statedAnnual report
「At a meeting of the Board of Directors held on 25 August 2016, we resolved the terms of the offering of stock acquisition rights to be issued to our directors as follows.」
We allocated 8,129 stock acquisition rights with a total underlying share amount of 81,290 shares, structured as stock-based compensation, to 3 directors excluding outside directors. The exercise period is from 15 September 2016 to 14 September 2046, and the exercise price is ¥1 per share.